SIGY (Sigyn Therapeutics) EBIT per Share: $-1.67 (TTM As of Sep. 2025)


What is Sigyn Therapeutics EBIT per Share?

Sigyn Therapeutics SIGY EBIT per Share is $-1.67 as of Sep. 2025. The stock has 3 warning signs investors should review. Among 1,172 Biotechnology companies, Sigyn Therapeutics ranks worse than 64.25% on this metric.

Sigyn Therapeutics's EBIT per Share for the three months ended in Sep. 2025 was $-0.24. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2025 was $-1.67.

During the past 3 years, the average EBIT per Share Growth Rate was 5.00% per year. During the past 5 years, the average EBIT per Share Growth Rate was 38.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Sigyn Therapeutics's EBIT per Share or its related term are showing as below:

SIGY' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -48.4   Med: 23.5   Max: 73
Current: 5

During the past 11 years, the highest 3-Year average EBIT per Share Growth Rate of Sigyn Therapeutics was 73.00% per year. The lowest was -48.40% per year. And the median was 23.50% per year.

SIGY's 3-Year EBIT Growth Rate is ranked worse than
64.25% of 1172 companies
in the Biotechnology industry
Industry Median: 15.4 vs SIGY: 5.00

Sigyn Therapeutics's EBIT for the three months ended in Sep. 2025 was $-0.39 Mil.

Sigyn Therapeutics  (OTCPK:SIGY) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Sigyn Therapeutics EBIT per Share Related Terms

Sigyn Therapeutics EBIT per Share Historical Data

* Premium members only.

The historical data trend for Sigyn Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sigyn Therapeutics EBIT per Share Chart

Sigyn Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.98 -2.80 -2.30 -1.91 -1.86

Sigyn Therapeutics Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.66 -0.26 -0.34 -0.83 -0.24

Sigyn Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Sigyn Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2024 is calculated as

EBIT per Share(A: Dec. 2024 )
=EBIT/Shares Outstanding (Diluted Average)
=-2.48/1.332
=-1.86

Sigyn Therapeutics's EBIT per Share for the quarter that ended in Sep. 2025 is calculated as

EBIT per Share(Q: Sep. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-0.387/1.605
=-0.24

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of $-1.67 mean?
Sigyn Therapeutics (SIGY) has a EBIT per Share of $-1.67 as of Sep. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Sigyn Therapeutics and its competitors. According to the industry distribution chart, Sigyn Therapeutics ranks #753 out of 1172 companies in the Biotechnology industry, placing it in the top 64.2%.
Is Sigyn Therapeutics' EBIT per Share too high?
Sigyn Therapeutics' current EBIT per Share is $-1.67. Based on the distribution chart, Sigyn Therapeutics ranks #753 out of 1172 companies in the Biotechnology industry, which is below the industry midpoint.
How does Sigyn Therapeutics' EBIT per Share compare to RGBP and ENDV?
According to the Biotechnology industry distribution chart, Sigyn Therapeutics ranks #753 out of 1172 companies for EBIT per Share. This places Sigyn Therapeutics in the lower half of its industry. The industry median EBIT per Share is 15.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,172 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Sigyn Therapeutics and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sigyn Therapeutics's current EBIT per Share is $-1.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sigyn Therapeutics stock overvalued right now?
Sigyn Therapeutics (SIGY) has a current EBIT per Share of $-1.67. The current EBIT per Share is $-1.67. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Sigyn Therapeutics (SIGY), the current EBIT per Share is $-1.67 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sigyn Therapeutics Business Description

Address 2468 Historic Decatur Road, Suite 140, San Diego, CA, USA, 92106
Sigyn Therapeutics Inc is a development-stage therapeutic technology company. Its business focus is the clinical advancement of Sigyn Therapy, a multi-function blood purification technology designed to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory disorders, including sepsis, the cause of hospital deaths world-wide. To support widespread implementation, the company designed Sigyn Therapy to be a single-use disposable device that is deployable on the world-wide infrastructure of hemodialysis and continuous renal replacement therapy machines already located in hospitals and clinics.